Cited by 476Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatmentsCancer-related cognitive impairment studies

The DOI matches its Crossref record; 58 of the 58 references it cites were found in a registry or an index.

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

Open access

Morris, John C., Roe, Catherine M., Grant, Elizabeth A., Head, Denise, Storandt, Martha, Goate, Alison M., Fagan, Anne M., Holtzman, David M., Mintun, Mark A.·2009·Archives of Neurology

DOI 10.1001/archneurol.2009.269PMC PMC2798814

Open this paper in CoChat — free account Open PDF

Abstract

OBJECTIVE: To determine whether preclinical Alzheimer disease (AD), as detected by the amyloid-imaging agent Pittsburgh Compound B (PiB) in cognitively normal older adults, is associated with risk of symptomatic AD. DESIGN: A longitudinal cohort study of cognitively normal older adults assessed with positron emission tomography (PET) to determine the mean cortical binding potential for PiB and followed up with annual clinical and cognitive assessments for progression to very mild dementia of the Alzheimer type (DAT). SETTING: The Alzheimer's Disease Research Center, Washington University, St Louis, Missouri. PARTICIPANTS: One hundred fifty-nine participants with a mean age of 71.5 years with a Clinical Dementia Rating (CDR) of 0 on a PET PiB scan at baseline. MAIN OUTCOME MEASURE: Progression from CDR 0 to CDR 0.5 status (very mild dementia). RESULTS: Twenty-three participants progressed to CDR 0.5 at follow-up assessment (range, 1-5 assessments after PET PiB). Of these, 9 also were diagnosed with DAT. Higher mean cortical binding potential values for PiB (hazard ratio, 4.85; 95% confidence interval, 1.22-19.01; P = .02) and age (hazard ratio, 1.14; 95% confidence interval, 1.02-1.28; P = .03) predicted progression to CDR 0.5 DAT. The CDR 0.5 DAT group showed decline in 3 cognitive domains (episodic memory, semantic memory, and visuospatial performance) and had volume loss in the parahippocampal gyrus (includes entorhinal cortex) compared with individuals who remained at CDR 0. CONCLUSION: Preclinical AD as detected by PET PiB is not benign, as it is associated with progression to symptomatic AD.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1001/archneurol.2009.269

Cites

58 of 58 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

“Mini-mental state”
Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975) · Journal of Psychiatric Research · doi:10.1016/0022-3956(75)90026-6 · Cited by 88,282
An automated labeling system for subdividing the human cerebral cortex on MRI scans into gyral based regions of interest
Desikan, R. S., Ségonne, F., Fischl, B., Quinn, B. T., Dickerson, B. C., Blacker, D., Buckner, R. L., Dale, A. M., Maguire, R. P., Hyman, B. T., et al. (2006) · NeuroImage · doi:10.1016/j.neuroimage.2006.01.021 · Cited by 13,324
The Clinical Dementia Rating (CDR): Current version and scoring rules
Morris, J. C. (1993) · Neurology · doi:10.1212/wnl.43.11.2412-a · Cited by 9,882
Self-citation
Co-planar stereotaxic atlas of the human brain : 3-dimensional proportional system : an approach to cerebral imaging
Talairach, J., Tournoux, P., & Rayport, M. (1988) · Thieme eBooks · Cited by 5,058
Manual for the Wechsler Adult Intelligence Scale.
Wechsler, D. (1955) · Psychological Corp. eBooks · Cited by 4,941
Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B
Klunk, W. E., Engler, H., Nordberg, A., Wang, Y., Blomqvist, G., Holt, D. P., Bergström, M., Savitcheva, I., Huang, G., Estrada, S., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20009 · Cited by 4,496
Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects
Shaw, L. M., Vanderstichele, H., Knapik‐Czajka, M., Clark, C. M., Aisen, P. S., Petersen, R. C., Blennow, K., Soares, H., Simon, A., Lewczuk, P., et al. (2009) · Annals of Neurology · doi:10.1002/ana.21610 · Cited by 2,065
Mild Cognitive Impairment Represents Early-Stage Alzheimer Disease
Morris, J. C., Storandt, M., Miller, J. P., McKeel, D. W., Price, J. L., Rubin, E. H., & Berg, L. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.397 · Cited by 1,871
Self-citation
Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700
Distribution Volume Ratios without Blood Sampling from Graphical Analysis of PET Data
Logan, J., Fowler, J. S., Volkow, N. D., Wang, G., Ding, Y., & Alexoff, D. L. (1996) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1097/00004647-199609000-00008 · Cited by 1,515

Show all 57 references

Sorted by citations

Items 101–200 of 469

Long-TermIn VivoImaging of β-Amyloid Plaque Appearance and Growth in a Mouse Model of Cerebral β-Amyloidosis
Hefendehl, J. K., Wegenast‐Braun, B. M., Liebig, C., Eicke, D., Milford, D., Calhoun, M. E., Kohsaka, S., Eichner, M., & Jucker, M. (2011) · Journal of Neuroscience · doi:10.1523/jneurosci.5147-10.2011 · Cited by 143
Amyloid-β–Associated Clinical Decline Occurs Only in the Presence of Elevated P-tau
Desikan, R. S., McEvoy, L. K., Thompson, W. K., Holland, D., Brewer, J. B., Aisen, P. S. S., Sperling, R. A., Dale, A. M., & Initiative, A. D. N. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.3354 · Cited by 139
Brain imaging in the study of Alzheimer's disease
Reiman, E. M., & Jagust, W. J. (2011) · NeuroImage · doi:10.1016/j.neuroimage.2011.11.075 · Cited by 139
Vascular amyloidosis impairs the gliovascular unit in a mouse model of Alzheimer’s disease
Kimbrough, I. F., Robel, S., Roberson, E. D., & Sontheimer, H. W. (2015) · Brain · doi:10.1093/brain/awv327 · Cited by 140
PET staging of amyloidosis using striatum
Hanseeuw, B. J., Betensky, R. A., Mormino, E. C., Schultz, A. P., Sepulcre, J., Becker, J. A., Jacobs, H. I. L., Buckley, R. F., LaPoint, M. R., Vannini, P., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.04.011 · Cited by 134
A high-glycemic diet is associated with cerebral amyloid burden in cognitively normal older adults
Taylor, M. K., Sullivan, D. K., Swerdlow, R. H., Vidoni, E. D., Morris, J. K., Mahnken, J. D., & Burns, J. M. (2017) · American Journal of Clinical Nutrition · doi:10.3945/ajcn.117.162263 · Cited by 145
Self-citation
The Earliest Stage of Cognitive Impairment in Transition From Normal Aging to Alzheimer Disease Is Marked by Prominent RNA Oxidation in Vulnerable Neurons
Nunomura, A., Tamaoki, T., Motohashi, N., Nakamura, M., McKeel, D. W., Tabaton, M., Lee, H., Smith, M. A., Perry, G. L., & Zhu, X. (2012) · Journal of Neuropathology & Experimental Neurology · doi:10.1097/nen.0b013e318248e614 · Cited by 134
Cerebral amyloid PET imaging in Alzheimer’s disease
Jack, C. R., Barrio, J. R., & Kepe, V. (2013) · Acta Neuropathologica · doi:10.1007/s00401-013-1185-7 · Cited by 137
Amyloid imaging as a biomarker for cerebral β-amyloidosis and risk prediction for Alzheimer dementia
Klunk, W. E. (2011) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.09.006 · Cited by 131
Cerebrovascular disease, beta-amyloid, and cognition in aging
Marchant, N. L., Reed, B. R., DeCarli, C. S., Madison, C. M., Weiner, M. W., Chui, H. C., & Jagust, W. J. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.10.001 · Cited by 127
Voxel-based meta-analysis of grey matter changes in Alzheimer’s disease
Wang, W., Yu, J., Liu, Y., Yin, R., Wang, H.-F., Wang, J., Tan, L., Raduà, J., & Tan, L. (2015) · Translational Neurodegeneration · doi:10.1186/s40035-015-0027-z · Cited by 124
Amyloid deposition detected with florbetapir F 18 (18F-AV-45) is related to lower episodic memory performance in clinically normal older individuals
Sperling, R. A., Johnson, K. A., Doraiswamy, P. M., Reiman, E. M., Fleisher, A., Sabbagh, M. N., Sadowsky, C., Carpenter, A. P., Davis, M. D., Lu, M., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.06.014 · Cited by 127
Self-citation
The aging brain and cognition: contribution of vascular injury and aβ to mild cognitive dysfunction
Marchant, N. L., Reed, B. R., Sanossian, N., Madison, C. M., Kriger, S., Dhada, R., Mack, W. J., DeCarli, C., Weiner, M. W., Mungas, D. M., et al. (2013) · JAMA Neurology · doi:10.1001/2013.jamaneurol.405 · Cited by 106
Biomarkers in Alzheimer's disease drug development
Cummings, J. L. (2011) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2010.06.004 · Cited by 122
Harmonized diagnostic criteria for Alzheimer's disease: recommendations
Morris, J. C., Blennow, K., Froelich, L., Nordberg, A. K., Soininen, H. S., Waldemar, G., Wahlund, L., & Dubois, B. (2014) · Journal of Internal Medicine · doi:10.1111/joim.12199 · Cited by 122
Self-citation
Regional expansion of hypometabolism in Alzheimer's disease follows amyloid deposition with temporal delay
Förster, S., Grimmer, T., Miederer, I., Henriksen, G., Yousefi, B. H., Graner, P., Wester, H.-J., Förstl, H., Kurz, A., Dickerson, B. C., et al. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2011.04.023 · Cited by 119
Identifying incipient dementia individuals using machine learning and amyloid imaging
Mathotaarachchi, S., Pascoal, T. A., Shin, M., Benedet, A. L., Kang, M. S., Beaudry, T., Fonov, V. S., Gauthier, S., & Rosa-Neto, P. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.06.027 · Cited by 118
Mild Cognitive Impairment in Older Adults
Geda, Y. E. (2012) · Current Psychiatry Reports · doi:10.1007/s11920-012-0291-x · Cited by 124
In vivo characterization of the early states of the amyloid-beta network
Sepulcre, J., Sabuncu, M. R., Becker, A., Sperling, R., & Johnson, K. A. (2013) · Brain · doi:10.1093/brain/awt146 · Cited by 117
Spatial patterns of brain amyloid- burden and atrophy rate associations in mild cognitive impairment
Tosun, D., Schuff, N. W., Mathis, C. A., Jagust, W., Weiner, M. W., & Initiative, A. D. N. (2011) · Brain · doi:10.1093/brain/awr044 · Cited by 122
Light-Induced Pupillary Responses in Alzheimer's Disease
Chougule, P. S., Najjar, R. P., Finkelstein, M. T., Kandiah, N., & Miléa, D. (2019) · Frontiers in Neurology · doi:10.3389/fneur.2019.00360 · Cited by 122
The therapeutics of Alzheimer's disease: Where we stand and where we are heading
Selkoe, D. J. (2013) · Annals of Neurology · doi:10.1002/ana.24001 · Cited by 116
Aβ-amyloid and Tau Imaging in Dementia
Villemagne, V. L., Doré, V., Bourgeat, P., Burnham, S. C., Laws, S., Salvado, O., Masters, C. L., & Rowe, C. C. (2017) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.006 · Cited by 110
Dual-Biomarker Imaging of Regional Cerebral Amyloid Load and Neuronal Activity in Dementia with PET and 11C-Labeled Pittsburgh Compound B
Meyer, P. T., Hellwig, S., Amtage, F., Rottenburger, C., Sahm, U., Reuland, P., Weber, W., & Hüll, M. (2011) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.083683 · Cited by 112
Psychological, behavioral and social effects of disclosing Alzheimer’s disease biomarkers to research participants: a systematic review
Bemelmans, S. A. S. A., Tromp, K., Bunnik, E. M., Milne, R., Badger, S. J., Brayne, C., Schermer, M., & Richard, E. (2016) · Alzheimer s Research & Therapy · doi:10.1186/s13195-016-0212-z · Cited by 112
Roles of brain-derived neurotrophic factor/tropomyosin-related kinase B (BDNF/TrkB) signalling in Alzheimer’s disease
Zhang, F., Kang, Z., Li, W., Xiao, Z., & Zhou, X. (2012) · Journal of Clinical Neuroscience · doi:10.1016/j.jocn.2011.12.022 · Cited by 110
Ocular Biomarkers for Early Detection of Alzheimer's Disease
Frost, S. M., Martins, R. N., & Kanagasingam, Y. (2010) · Journal of Alzheimer s Disease · doi:10.3233/jad-2010-100819 · Cited by 109
Diagnostic accuracy of CSF Ab42 and florbetapir PET for Alzheimer's disease
Mattsson, N., Insel, P. S., Landau, S. M., Jagust, W., Donohue, M., Shaw, L. M. J., Trojanowski, J. Q., Zetterberg, H., Blennow, K., Weiner, M. W., et al. (2014) · Annals of Clinical and Translational Neurology · doi:10.1002/acn3.81 · Cited by 108
Revolutionizing Alzheimer's disease and clinical trials through biomarkers
Mattsson, N., Carrillo, M. C., Dean, R. A., Devous, M. D., Nikolcheva, T., Pesini, P., Salter, H., Potter, W. Z., Sperling, R. A., Bateman, R. J., et al. (2015) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1016/j.dadm.2015.09.001 · Cited by 102
Assessing the progression of mild cognitive impairment to Alzheimer's disease: current trends and future directions
Brooks, L., & Loewenstein, D. (2010) · Alzheimer s Research & Therapy · doi:10.1186/alzrt52 · Cited by 107
Relationship of dementia screening tests with biomarkers of Alzheimer's disease
Galvin, J. E., Fagan, A. M., Holtzman, D. M., Mintun, M. A., & Morris, J. C. (2010) · Brain · doi:10.1093/brain/awq204 · Cited by 103
Self-citation
In vivo assessment of amyloid‐β deposition in nondemented very elderly subjects
Mathis, C. A., Kuller, L. H., Klunk, W. E., Snitz, B. E., Price, J. C., Weissfeld, L. A., Rosario, B. L., Lopresti, B. J., Saxton, J. A., Aizenstein, H. J., et al. (2013) · Annals of Neurology · doi:10.1002/ana.23797 · Cited by 98
Short-term Psychological Outcomes of Disclosing Amyloid Imaging Results to Research Participants Who Do Not Have Cognitive Impairment
Grill, J. D., Raman, R., Ernstrom, K. B., Sultzer, D. L., Burns, J. M., Donohue, M., Johnson, K. A., Aisen, P. S. S., Sperling, R. A., Karlawish, J. H., et al. (2020) · JAMA Neurology · doi:10.1001/jamaneurol.2020.2734 · Cited by 101
Neurodegenerative disease diagnosis using incomplete multi-modality data via matrix shrinkage and completion
Thung, K., Chong-yaw Wee, A., Yap, P., & Shen, D. G. (2014) · NeuroImage · doi:10.1016/j.neuroimage.2014.01.033 · Cited by 98
Preclinical Alzheimer disease and risk of falls
Stark, S. L., Roe, C. M., Grant, E., Hollingsworth, H. H., Benzinger, T. L. S., Fagan, A. M., Buckles, V., & Morris, J. C. (2013) · Neurology · doi:10.1212/wnl.0b013e31829d8599 · Cited by 99
Self-citation
Brain aerobic glycolysis functions and Alzheimer’s disease
Vlassenko, A. G., & Raichle, M. E. (2014) · Clinical and Translational Imaging · doi:10.1007/s40336-014-0094-7 · Cited by 96
Transforming cerebrospinal fluid Aβ42 measures into calculated Pittsburgh compound B units of brain Aβ amyloid
Weigand, S. D., Vemuri, P., Wiste, H. J., Senjem, M. L., Pankratz, V. S., Aisen, P. S., Weiner, M. W., Petersen, R. C., Shaw, L. M., Trojanowski, J. Q., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2010.08.230 · Cited by 93
Association of Brain Amyloid-β With Slow Gait in Elderly Individuals Without Dementia
Nadkarni, N. K., Perera, S., Snitz, B. E., Mathis, C. A., Price, J. C., Williamson, J. D., DeKosky, S. T., Klunk, W. E., & López, O. L. (2016) · JAMA Neurology · doi:10.1001/jamaneurol.2016.3474 · Cited by 94
Early Detection of Amyloidopathy in Alzheimer's Mice by Hyperspectral Endoscopy
More, S. S., Beach, J. M., & Vince, R. (2016) · Investigative Ophthalmology & Visual Science · doi:10.1167/iovs.15-17406 · Cited by 97
Altered Gray Matter Structural Covariance Networks in Early Stages of Alzheimer's Disease
Montembeault, M., Rouleau, I., Provost, J.-S., & Brambati, S. M. (2015) · Cerebral Cortex · doi:10.1093/cercor/bhv105 · Cited by 94
Signs and Artifacts in Amyloid PET
Lundeen, T. F., Seibyl, J. P., Covington, M. F., Eshghi, N., & Kuo, P. H. (2018) · Radiographics · doi:10.1148/rg.2018180160 · Cited by 91
Quantitative structural MRI for early detection of Alzheimer's disease
McEvoy, L. K., & Brewer, J. B. (2010) · Expert Review of Neurotherapeutics · doi:10.1586/ern.10.162 · Cited by 90
A Disease State Fingerprint for Evaluation of Alzheimer's Disease
Mattila, J., Initiative, A. F. T. A. D. N., Koikkalainen, J. R., Virkki, A., Simonsen, A. H., van Gils, M., Waldemar, G., Soininen, H. S., & Lötjönen, J. M. P. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110365 · Cited by 89
Nutrient intake and brain biomarkers of Alzheimer's disease in at-risk cognitively normal individuals: a cross-sectional neuroimaging pilot study
Mosconi, L., Murray, J., Davies, M., Williams, S., Pirraglia, E., Spector, N. C., Tsui, W. H., Li, Y., Butler, T., Osorio, R. S., et al. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004850 · Cited by 89
Predicting Symptom Onset in Sporadic Alzheimer Disease With Amyloid PET
Schindler, S. E., Li, Y., Buckles, V. D., Gordon, B. A., Benzinger, T. L. S., Wang, G., Coble, D., Klunk, W. E., Fagan, A. M., Holtzman, D. M., et al. (2021) · Neurology · doi:10.1212/wnl.0000000000012775 · Cited by 89
Self-citation
Protein Binding in Patients With Late-Life Depression
Kumar, A. (2011) · Archives of General Psychiatry · doi:10.1001/archgenpsychiatry.2011.122 · Cited by 86
Cognitive trajectories associated with β-amyloid deposition in the oldest-old without dementia
Snitz, B. E., Weissfeld, L. A., López, O. L., Kuller, L. H., Saxton, J. A., Singhabahu, D., Klunk, W. E., Mathis, C. A., Price, J. C., Ives, D. G., et al. (2013) · Neurology · doi:10.1212/wnl.0b013e31828c2fc8 · Cited by 88
Cerebrospinal Fluid Biomarkers of Alzheimer's Disease
Fagan, A. M., & Holtzman, D. M. (2010) · Biomarkers in Medicine · doi:10.2217/bmm.09.83 · Cited by 88
Self-citation
Clinical meaningfulness of subtle cognitive decline on longitudinal testing in preclinical AD
Papp, K. V., Buckley, R. F., Mormino, E. C., Maruff, P. T., Villemagne, V. L., Masters, C. L., Johnson, K. A., Rentz, D. M., Sperling, R. A., Amariglio, R. E., et al. (2019) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2019.09.074 · Cited by 85
Cognitive Impairment Precedes and Predicts Functional Impairment in Mild Alzheimer’s Disease
Liu‐Seifert, H., Initiative, T. A. D. N., Siemers, E., Price, K., Han, B., Selzler, K. J., Henley, D. B., Sundell, K. L., Aisen, P. S. S., Cummings, J. L., et al. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-142508 · Cited by 90
Depressive and anxiety symptoms and cortical amyloid deposition among cognitively normal elderly persons: the Mayo Clinic Study of Aging
Krell‐Roesch, J., Lowe, V. J., Neureiter, J., Pink, A., Roberts, R. O., Mielke, M. M., Vemuri, P., Stokin, G. B., Christianson, T. J. H., Jack, C. R., et al. (2017) · International Psychogeriatrics · doi:10.1017/s1041610217002368 · Cited by 81
Safety of disclosing amyloid status in cognitively normal older adults
Burns, J. M., Johnson, D. K., Liebmann, E. P., Bothwell, R. J., Morris, J. K., & Vidoni, E. D. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2017.01.022 · Cited by 80
Self-citation
Amyloid imaging in the differential diagnosis of dementia: review and potential clinical applications
Laforce, R., & Rabinovici, G. D. (2011) · Alzheimer's Research & Therapy · doi:10.1186/alzrt93 · Cited by 79
Prevention trials in Alzheimer's disease: An EU-US task force report
Vellas, B. J., Aisen, P. S. S., Sampaio, C., Carrillo, M. C., Scheltens, P., Scherrer, B., Frisoni, G. B., Weiner, M. W., Schneider, L. S. S., Gauthier, S. G., et al. (2011) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2011.08.014 · Cited by 78
Preclinical Alzheimer's disease: A systematic review of the cohorts underlying the concept
Epelbaum, S., Genthon, R., Cavedo, E., Habert, M. O., Lamari, F., Gagliardi, G. P., Lista, S., Teichmann, M., Bakardjian, H., Hampel, H. J., et al. (2017) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2016.12.003 · Cited by 82
Neuropsychological measures that detect early impairment and decline in preclinical Alzheimer disease
Schindler, S. E., Jasielec, M. S., Weng, H., Hassenstab, J. J., Grober, E. H., McCue, L. M., Morris, J. C., Holtzman, D. M., Xiong, C., & Fagan, A. M. (2017) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2017.04.004 · Cited by 77
Self-citation
PET imaging with [18F]AV-45 in an APP/PS1-21 murine model of amyloid plaque deposition
Poisnel, G., Dhilly, M., Moustié, O., Delamare, J., Abbas, A., Guilloteau, D., & Barré, L. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.12.024 · Cited by 79
Association Between Childhood-Onset Epilepsy and Amyloid Burden 5 Decades Later
Joutsa, J., Rinne, J. O., Hermann, B. P., Karrasch, M., Anttinen, A., Shinnar, S., & Sillanpää, M. L. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2016.6091 · Cited by 79
Striatal amyloid plaque density predicts braak neurofibrillary stage and clinicopathological Alzheimer's disease: Implications for amyloid imaging
Beach, T. G., Sue, L. I., Walker, D. G., Sabbagh, M. N., Serrano, G., Dugger, B. N., Mariner, M., Yantos, K., Henry-Watson, J., Chiarolanza, G., et al. (2012) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-111340 · Cited by 74
Safety and efficacy of lecanemab for Alzheimer's disease: a systematic review and meta-analysis of randomized clinical trials
Qiao, Y., Chi, Y., Zhang, Q., & Ma, Y. (2023) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2023.1169499 · Cited by 78
Peripheral Blood Mononuclear Cells as a Laboratory to Study Dementia in the Elderly
Arosio, B., D’Addario, C., Gussago, C., Casati, M., Tedone, E., Ferri, E., Nicolini, P., Rossi, P. D., Maccarrone, M., & Mari, D. (2014) · BioMed Research International · doi:10.1155/2014/169203 · Cited by 73
Cerebral Serotonin 4 Receptors and Amyloid-β in Early Alzheimer's Disease
Madsen, K., Neumann, W., Holst, K. K., Marner, L., Haahr, M. E., Lehel, S., Knudsen, G. M., & Hasselbalch, S. G. (2011) · Journal of Alzheimer s Disease · doi:10.3233/jad-2011-110056 · Cited by 74
Preclinical AD Workgroup staging: Pathological correlates and potential challenges
Jicha, G. A., Abner, E. L., Schmitt, F. A., Kryscio, R. J., Riley, K. P., Cooper, G. E., Stiles, N., Mendiondo, M. S., Smith, C. D., Van Eldik, L. J., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.02.018 · Cited by 71
Comparison of CSF markers and semi-quantitative amyloid PET in Alzheimer’s disease diagnosis and in cognitive impairment prognosis using the ADNI-2 database
(ADNI), T. A. D. N. I., Bouallègue, F. B., Mariano‐Goulart, D., & Payoux, P. (2017) · Alzheimer s Research & Therapy · doi:10.1186/s13195-017-0260-z · Cited by 73
Enrichment and Stratification for Predementia Alzheimer Disease Clinical Trials
Holland, D., McEvoy, L. K., Desikan, R. S., Dale, A. M., & Initiative, A. D. N. (2012) · PLoS ONE · doi:10.1371/journal.pone.0047739 · Cited by 71
Derivation of a New ADAS-cog Composite Using Tree-based Multivariate Analysis
Llano, D. A., Laforet, G. A., & Devanarayan, V. (2010) · Alzheimer Disease & Associated Disorders · doi:10.1097/wad.0b013e3181f5b8d8 · Cited by 70
Deficits in Spontaneous Cognition as an Early Marker of Alzheimer’s Disease
Kvavilashvili, L., Niedźwieńska, A., Gilbert, S. J., & Markostamou, I. (2020) · Trends in Cognitive Sciences · doi:10.1016/j.tics.2020.01.005 · Cited by 74
The Role of P2X7 Receptor in Alzheimer’s Disease
Francistiová, L., Bianchi, C., Lauro, C. D., Sebastián‐Serrano, Á., de Diego-García, L., Kobolák, J., Dinnyés, A., & Díaz-Hernández, M. (2020) · Frontiers in Molecular Neuroscience · doi:10.3389/fnmol.2020.00094 · Cited by 73
Characterization of plasma β-secretase (BACE1) activity and soluble amyloid precursor proteins as potential biomarkers for Alzheimer’s disease
Wu, G., Sankaranarayanan, S., Wong, J., Tugusheva, K., Michener, M. S., Shi, X., Cook, J. J., Simon, A. J., & Savage, M. J. (2012) · Journal of Neuroscience Research · doi:10.1002/jnr.23122 · Cited by 68
In vivo detection of microstructural correlates of brain pathology in preclinical and early Alzheimer Disease with magnetic resonance imaging
Zhao, Y., Raichle, M. E., Wen, J., Benzinger, T. L. S., Fagan, A. M., Hassenstab, J. J., Vlassenko, A. G., Luo, J., Cairns, N. J., Christensen, J. J., et al. (2016) · NeuroImage · doi:10.1016/j.neuroimage.2016.12.026 · Cited by 69
Self-citation
The effect of amyloid β on cognitive decline is modulated by neural integrity in cognitively normal elderly
Wirth, M., Oh, H., Mormino, E. C., Markley, C., Landau, S. M., & Jagust, W. J. (2013) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2012.10.012 · Cited by 70
Combined Plasma and Cerebrospinal Fluid Signature for the Prediction of Midterm Progression From Mild Cognitive Impairment to Alzheimer Disease
Lehallier, B., Essioux, L., Gayán, J., Alexandridis, R. A., Nikolcheva, T., Wyss‐Coray, T., Britschgi, M., & Initiative, A. D. N. (2015) · JAMA Neurology · doi:10.1001/jamaneurol.2015.3135 · Cited by 69
Lack of association between prior depressive episodes and cerebral [11C]PiB binding
Madsen, K., Hasselbalch, B. J., Frederiksen, K. S., Haahr, M. E., Gade, A., Law, I., Price, J. C., Knudsen, G. M., Kessing, L. V., & Hasselbalch, S. G. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2011.11.021 · Cited by 66
Target-Specific PET Probes for Neurodegenerative Disorders Related to Dementia
Kadir, A., & Nordberg, A. K. (2010) · Journal of Nuclear Medicine · doi:10.2967/jnumed.110.077164 · Cited by 64
Amyloid imaging: Past, present and future perspectives
Villemagne, V. L. (2016) · Ageing Research Reviews · doi:10.1016/j.arr.2016.01.005 · Cited by 68
Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions
Ossenkoppele, R., van der Flier, W. M., Verfaillie, S. C. J., Vrenken, H., Versteeg, A., van Schijndel, R. A., Sikkes, S. A. M., Twisk, J. W. R., Adriaanse, S. M., Zwan, M. D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000432 · Cited by 63
Cardiorespiratory Fitness Attenuates the Influence of Amyloid on Cognition
Schultz, S. A., Boots, E. A., Almeida, R. P., Oh, J. M., Einerson, J. A., Korcarz, C. E., Edwards, D. F., Koscik, R. L., Dowling, N. M., Gallagher, C. L., et al. (2015) · Journal of the International Neuropsychological Society · doi:10.1017/s1355617715000843 · Cited by 65
Widespread distribution of tauopathy in preclinical Alzheimer's disease
Schultz, S. A., Gordon, B. A., Mishra, S., Su, Y., Perrin, R. J., Cairns, N. J., Morris, J. C., Ances, B. M., & Benzinger, T. L. S. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.08.022 · Cited by 65
Self-citation
Clinical Amyloid Imaging
Mallik, A. K., Drzezga, A. E., & Minoshima, S. (2016) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2016.09.005 · Cited by 64
Amyloid Imaging with PET in Early Alzheimer Disease Diagnosis
Rowe, C. C., & Villemagne, V. L. (2013) · Medical Clinics of North America · doi:10.1016/j.mcna.2012.12.017 · Cited by 62
Amyloid imaging, Risk Disclosure and Alzheimer’s Disease: Ethical and Practical Issues
Roberts, J. S., Dunn, L. B., & Rabinovici, G. D. (2013) · Neurodegenerative Disease Management · doi:10.2217/nmt.13.25 · Cited by 64
Gadolinium-based contrast agents targeted to amyloid aggregates for the early diagnosis of Alzheimer's disease by MRI
Bort, G., Catoen, S., Borderies, H., Kebsi, A., Ballet, S., Louin, G., Port, M., & Ferroud, C. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.10.016 · Cited by 62
Secondary prevention of Alzheimer’s dementia: neuroimaging contributions
ten Kate, M., Ingala, S., Schwarz, A. J., Fox, N. C., Chételat, G., van Berckel, B. N. M., Ewers, M., Foley, C., Gispert, J. D., Hill, D., et al. (2018) · Alzheimer s Research & Therapy · doi:10.1186/s13195-018-0438-z · Cited by 65
Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals
Ingala, S., Tomassen, J., Collij, L. E., Prent, N., Ent, D. V. ‘., ten Kate, M., Konijnenberg, E., Yaqub, M. M., Scheltens, P., de Geus, E. J. C., et al. (2021) · Brain Communications · doi:10.1093/braincomms/fcab201 · Cited by 65
In vitro characterization of [18F]-florbetaben, an Aβ imaging radiotracer
Fodero‐Tavoletti, M. T., Brockschnieder, D., Villemagne, V. L., Martin, L., Connor, A. R., Thiele, A., Berndt, M., McLean, C., Krause, S., Rowe, C. C., et al. (2012) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2012.03.001 · Cited by 61
Estimating sample sizes for predementia Alzheimer's trials based on the Alzheimer's Disease Neuroimaging Initiative
Grill, J. D., Di, L., Lu, P. H., Lee, C., Ringman, J., Apostolova, L. G., Chow, N., Kohannim, O., Cummings, J. L., Thompson, P. M., et al. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2012.03.006 · Cited by 58
Bapineuzumab: Anti-β-Amyloid Monoclonal Antibodies for the Treatment of Alzheimer‘s Disease
Panza, F., Frisardi, V., Imbimbo, B. P., D’Onofrio, G., Pietrarossa, G., Seripa, D., Pilotto, A., & Solfrizzi, V. (2010) · Immunotherapy · doi:10.2217/imt.10.80 · Cited by 59
Neuroimaging Measures as Endophenotypes in Alzheimer′s Disease
Braskie, M. N., Ringman, J. M., & Thompson, P. M. (2011) · International Journal of Alzheimer s Disease · doi:10.4061/2011/490140 · Cited by 62
Molecular imaging in Alzheimer's disease: new perspectives on biomarkers for early diagnosis and drug development
Nordberg, A. K. (2011) · Alzheimer s Research & Therapy · doi:10.1186/alzrt96 · Cited by 58
Practice effects and longitudinal cognitive change in clinically normal older adults differ by Alzheimer imaging biomarker status
Machulda, M. M., Hagen, C. E., Wiste, H. J., Mielke, M. M., Knopman, D. S., Roberts, R. O., Vemuri, P., Lowe, V. J., Jack, C. R., & Petersen, R. C. (2016) · The Clinical Neuropsychologist · doi:10.1080/13854046.2016.1241303 · Cited by 63
Amyloid, neurodegeneration, and small vessel disease as predictors of dementia in the oldest-old
López, O. L., Klunk, W. E., Mathis, C. A., Coleman, R., Price, J. C., Becker, J. T., Aizenstein, H. J., Snitz, B. E., Cohen, A. D., Ikonomović, M. D., et al. (2014) · Neurology · doi:10.1212/wnl.0000000000000977 · Cited by 57
Hypertension and obesity moderate the relationship between β‐amyloid and cognitive decline in midlife
Clark, L. R., Koscik, R. L., Allison, S. L., Berman, S. E., Norton, D., Carlsson, C. M., Betthauser, T. J., Bendlin, B. B., Christian, B. T., Chin, N. A., et al. (2018) · Alzheimer s & Dementia · doi:10.1016/j.jalz.2018.09.008 · Cited by 57
A Comparison of the Diagnostic Sensitivity of MRI, CBF-SPECT, FDG-PET and Cerebrospinal Fluid Biomarkers for Detecting Alzheimer’s Disease in a Memory Clinic
Morinaga, A., Ono, K., Ikeda, T., Ikeda, Y., Shima, K., Noguchi‐Shinohara, M., Samuraki, M., Yanase, D., Yoshita, M., Iwasa, K., et al. (2010) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000320265 · Cited by 56
C5aR1 antagonism alters microglial polarization and mitigates disease progression in a mouse model of Alzheimer’s disease
Gómez-Arboledas, Á., Carvalho, K., Balderrama-Gutierrez, G., Chu, S., Liang, H. Y., Schartz, N. D., Selvan, P., Petrisko, T. J., Pan, M. A., Mortazavi, A., et al. (2022) · Acta Neuropathologica Communications · doi:10.1186/s40478-022-01416-6 · Cited by 57
Preclinical Alzheimer disease: identification of cases at risk among cognitively intact older individuals
Lazarczyk, M. J., Hof, P. R., Bouras, C., & Giannakopoulos, P. (2012) · BMC Medicine · doi:10.1186/1741-7015-10-127 · Cited by 55
Effect of apolipoprotein E4 on clinical, neuroimaging, and biomarker measures in noncarrier participants in the Dominantly Inherited Alzheimer Network
Bussy, A., Snider, B. J., Coble, D. W., Xiong, C., Fagan, A. M., Cruchaga, C., Benzinger, T. L. S., Gordon, B. A., Hassenstab, J. J., Bateman, R. J., et al. (2018) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2018.10.011 · Cited by 57
Self-citation
Self‐reported obstructive sleep apnea, amyloid and tau burden, and Alzheimer's disease time‐dependent progression
Bubu, O. M., Umasabor‐Bubu, O. Q., Turner, A. D., Parekh, A., Mullins, A. E., Kam, K., Birckbichler, M. K., Mukhtar, F., Mbah, A. K., Williams, N. J., et al. (2020) · Alzheimer s & Dementia · doi:10.1002/alz.12184 · Cited by 57
[11C]PIB, [18F]FDG and MR imaging in patients with mild cognitive impairment
Brück, A., Virta, J. R., Koivunen, J., Koikkalainen, J. R., Scheinin, N. M., Helenius, H. Y. M., Någren, K., Helin, S., Parkkola, R. K., Viitanen, M. H., et al. (2013) · European Journal of Nuclear Medicine and Molecular Imaging · doi:10.1007/s00259-013-2478-8 · Cited by 55
Disclosure of amyloid status is not a barrier to recruitment in preclinical Alzheimer's disease clinical trials
Grill, J. D., Zhou, Y. F., Elashoff, D. A., & Karlawish, J. H. (2015) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2015.11.007 · Cited by 53
FDG- and amyloid-PET in Alzheimer's disease: is the whole greater than the sum of the parts?
Mosconi, L., & McHugh, P. F. (2011) · PubMed · Cited by 54

Authors: Morris, J. C., Roe, C. M., Grant, E. A., Head, D., Storandt, M., Goate, A. M., Fagan, A. M., Holtzman, D. M., & Mintun, M. A.
Affiliations: Washington University in St. Louis (US)
ORCID: Morris, John C.
Roe, Catherine M.
Head, Denise
Goate, Alison M.
Fagan, Anne M.
Holtzman, David M.
Venue: Archives of Neurology
Publisher: American Medical Association (AMA)
Published: 2009-12-01
Volume: 66
Issue: 12
Pages: 1469-75
ISSN: 0003-9942 (ISSN-L)
DOI: 10.1001/archneurol.2009.269
PMC: PMC2798814
OpenAlex: W2031489026
Cited by: 476
References: 57
Citations by year: 2026: 5 · 2025: 7 · 2024: 4 · 2023: 14 · 2022: 10 · 2021: 15 · 2020: 46 · 2019: 13 · 2018: 17 · 2017: 24 · 2016: 22 · 2015: 24 · 2014: 43 · 2013: 58 · 2012: 50
FWCI: 35.46
Type: journal article
Language: en
Open access: bronze
doi.org
Locations: Archives of Neurology (publishedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: National Institutes of Health (UL1TR000448)
National Institute on Aging (P 50 AG05681, P50AG005681, P01 AG0 3991, P01AG003991, P01AG026276)
National Center for Research Resources (UL1RR024992)
National Center for Advancing Translational Sciences
Topics: Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
Health Sciences › Medicine › Oncology › Cancer-related cognitive impairment studies
Keywords: preclinical Alzheimer's disease, Pittsburgh compound B, amyloid PET, conversion to dementia, very mild dementia, cognitively normal older adults, Clinical Dementia Rating, episodic memory decline, visuospatial performance, entorhinal cortex, risk prediction
MeSH terms: Aged, Aged, 80 and over, Alzheimer Disease, Aniline Compounds, Carbon Radioisotopes, Cognition, Cognition Disorders, Female, Follow-Up Studies, Humans, Longitudinal Studies, Male, Middle Aged, Predictive Value of Tests, Thiazoles, Cohort Studies, Disease Progression, Positron-Emission Tomography

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Pittsburgh Compound B Imaging and Prediction of Progression From Cognitive Normality to Symptomatic Alzheimer Disease

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks